Previous 10 | Next 10 |
2024-01-10 13:17:03 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
NORTHAMPTON, MA / ACCESSWIRE / January 10, 2024 / Gilead Sciences: When employees at Gilead's recently opened New Jersey office need a place to meet, the "Cara" conference room is one such place they gather. Given the room's namesake, it's especially fitting when the topic at hand is the compan...
2024-01-10 10:58:13 ET Summary This article introduces a dividend stock selection process called YARP (Yield At a Reasonable Price) that prioritizes risk management and total return. YARP aims to identify stocks with historically high dividend yields that are currently undervalued...
2024-01-10 08:20:00 ET Summary The S&P500 delivered a strong year-end rally, gaining 4.5% in December and 26.3% for the year. Interest rates were kept steady in a range of 5.25% to 5.5% with the market expecting up to 6 decreases in 2024. Net investments of around $1,500 i...
2024-01-08 16:45:03 ET Gilead Sciences, Inc. (GILD) J.P. Morgan 42nd Annual Healthcare Conference January 08, 2023 01:30 PM ET Company Participants Dan O’Day - Chairman and CEO Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Office...
2024-01-08 08:31:52 ET Summary The healthcare sector was flat in 2023 year as a result of some unique issues. Drug price regulation will be a serious challenge for the sector this year. Defensive healthcare industry groups should do well during the first half and biotechnology...
2024-01-07 07:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The market bounced in ...
2024-01-05 09:07:57 ET More on Big Pharma Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Bri...
2024-01-05 10:17:57 ET More on Big Pharma Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Bri...
2024-01-04 13:51:02 ET More on BioNTech, Moderna, etc. Pfizer: If You Missed The Pandemic Entry, Here's Another Chance BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovatio...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...